Navigation Links
Watson to Distribute Alendronate Tablets
Date:2/5/2008

CORONA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the company expects to initiate shipments of alendronate sodium in the 35 and 70 mg once weekly dosage strengths when Fosamax(R) loses market exclusivity, which is anticipated to occur at the close of business on February 6, 2008. Alendronate sodium is the generic version of Merck's Fosamax(R) tablets, indicated for the treatment of osteoporosis in postmenopausal women. Alendronate sodium is also indicated to increase bone mass in men with osteoporosis.

Under the terms of a supply agreement, Merck will manufacture and supply the alendronate sodium tablets to Watson, which will market, sell and distribute the product in the United States. Merck will receive a share of the profits from Watson's sales of the generic product in the U.S. market. Further details on the agreement have not been disclosed.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

Fosamax(R) is a registered trademark of Merck and Co., Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives FDA Approval for Generic DuoNeb(R)
2. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
3. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
4. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
5. Watson Names Mark Durand Chief Financial Officer
6. Watson Files FDA Application for Generic YAZ(R)
7. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
10. HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools
11. CVS Caremark All Kids Can and Scholastic Distribute Free Educational Guides in Schools to Champion Acceptance and Build Self-Esteem among Second Graders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, Scanlan & ... announce Westchester resident Lauren C. Enea has joined the firm as an associate attorney. ... her practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion ... to Walk with God #TruthwithGrace” is the creation of published author Lea Michelle ...
(Date:3/23/2017)... Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... emergency and now estimates that there could be four million Zika-related cases in the ... to date with numbers of US cases reported per year skyrocketing to an estimated ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, ... Broadway Avenue, will be an educational and exciting program providing busy clinicians and ... of chronic pain. , Oklahoma is in a healthcare crisis. The state ranks ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017  GenomeDx Biosciences today announced that six abstracts ... Prostate Cancer Classifier tests will be presented at the ... Congress held March 24 to 28, 2017 in ... is Europe,s largest urological event ... urological field. The abstract titled "Muscle invasive ...
(Date:3/24/2017)... 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today disclosed terms ... Sheet (the "Definitive Financing") it entered into on ... stockholders, who are referred to in the Definitive ... filed with the Securities and Exchange Commission.   ...
(Date:3/23/2017)... based in St. Joseph, Missouri , has selected AccuReg to help ... in 22 cities, and its flagship St. Joseph Medical Center. Mosaic Life ... care to its patients, including the insurance, billing and collections processes. ... ... St. Joseph Medical Center ...
Breaking Medicine Technology: